RAD001

Phase 1/2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Tuberous Sclerosis

Conditions

Tuberous Sclerosis, Lymphangioleiomyomatosis

Trial Timeline

Aug 1, 2005 → Jul 1, 2013

NCT ID

NCT00457964

About RAD001

RAD001 is a phase 1/2 stage product being developed by Novartis for Tuberous Sclerosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00457964. Target conditions include Tuberous Sclerosis, Lymphangioleiomyomatosis.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (18)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01491672	Phase 2	Completed	Nov 1, 2011	May 1, 2015	Metastatic Renal Cell Carcinoma
NCT01324492	Phase 1	Completed	Dec 1, 2010	Jun 1, 2014	Lung Neuroendocrine Neoplasm
NCT01830153	Phase 2	Completed	Apr 1, 2010	—	Soft Tissue Sarcomas
NCT01048723	Phase 2	Terminated	Jan 1, 2010	Oct 1, 2011	Sarcoma
NCT01206764	Approved	Completed	Nov 11, 2009	Jul 1, 2017	Renal Cell Carcinoma
NCT00976248	Phase 2	Completed	Nov 1, 2009	Jul 1, 2018	Waldenstrom's Macroglobulinemia
NCT00688753	Phase 2	Completed	Jul 1, 2009	Oct 1, 2014	Carcinoma
NCT00936858	Phase 2	Completed	Jul 1, 2009	Feb 27, 2020	Thyroid Cancer
NCT00529802	Phase 2	Completed	Sep 1, 2007	Jul 1, 2010	Carcinoma, Renal Cell
NCT00516165	Phase 1/2	Completed	Aug 1, 2007	Nov 1, 2011	Hepatocellular Carcinoma
NCT00457119	Phase 1	Completed	Feb 1, 2007	Nov 1, 2009	Non Small Cell Lung Cancer
NCT00409292	Phase 2	Completed	Jan 1, 2007	May 1, 2009	Pancreatic Cancer
NCT00337545	Phase 2	Completed	May 1, 2006	Apr 1, 2007	Colorectal Cancer
NCT00457964	Phase 1/2	Completed	Aug 1, 2005	Jul 1, 2013	Tuberous Sclerosis
NCT00629525	Phase 2	Completed	Aug 1, 2005	Jan 1, 2010	Hormone Refractory Prostate Cancer
NCT00124280	Phase 2	Completed	Jul 1, 2005	—	Non-small-cell Lung Carcinoma
NCT00446368	Phase 2	Completed	May 1, 2005	Oct 1, 2008	Carcinoma, Renal Cell
NCT00081874	Phase 1/2	Completed	Apr 1, 2004	Sep 1, 2006	Leukemia

Competing Products

13 competing products in Tuberous Sclerosis

See all competitors

Product	Company	Stage	Hype Score
Everolimus (RAD001) + Everolimus Placebo	Novartis	Phase 3	77
Everolimus + Placebo	Novartis	Phase 3	77
Placebo + Everolimus (RAD001)	Novartis	Phase 2	52
RAD001 + Placebo	Novartis	Phase 2	52
RAD001 + Placebo + Antiepileptic drug (1 to 3 only) + open label RAD001 (only used for post-extension phase)	Novartis	Phase 3	77
Everolimus	Novartis	Phase 1/2	41
everolimus (RAD001)	Novartis	Phase 1/2	41
everolimus	Novartis	Phase 3	77
sirolimus	Pfizer	Phase 2	51
GWP42003-P	Jazz Pharmaceuticals	Phase 3	74
GWP42003-P	Jazz Pharmaceuticals	Phase 3	74
GWP42003-P + Placebo	Jazz Pharmaceuticals	Phase 3	74
Cannabidiol Oral Solution [Epidiolex]	Jazz Pharmaceuticals	Approved	82

Other Products from Novartis

LCZ696Approved

zoledronic acidApproved

NateglinideApproved

TenofovirApproved

FTY720Approved